Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Neuropsychopharmacology. 2014 Jun 11;39(12):2891–2899. doi: 10.1038/npp.2014.143

Table 2. Follow-up clinical measures in UHR participants.

UHR-R
N = 22		 UHR-NR
N = 29		 P
Thought Content abnormalities 0.2 (0.5) 3.6 (1.9) <0.001
Perception abnormalities 0.2 (0.5) 3.6 (1.9) <0.001
Speech abnormalities 0.7 (0.9) 2.1 (1.8) 0.001
Total attenuated positive symptoms 1.1 (1.3) 9.3 (3.9) <0.001
GAF score 72.5 (11.2) 54.6 (15.8) <0.001
PANSS-P 8.2 (1.7) 14.9 (4.9) <0.001
PANSS-N 8.3 (2.5) 11.2 (5.0) 0.02
PANSS-G 18.7 (3.7) 25.5 (7.5) 0.001
PANSS-T 35.2 (7.0) 51.6 (15.8) <0.001

Abbreviations. UHR-R: Ultra High Risk Remission; UHR-NR: No Remission; GAF: Global Assessment of Functioning scale; PANSS: Positive and Negative Syndrome Scale, P: positive; N: Negative; G: General and T: total.